ESR1 and cancer: The combination of 1 with other drugs in hybrid anti-cancer molecules has proven to be effective, e.g., as reported by Mendoza-Sanchez et al. [8] who developed a bifunctional anti-proliferative 1/estrogen receptor modulator ICI-164,384 compound active on both TNBC (MDA-MB-231) and estrogen receptor–positive (MCF-7) cells.